You are here: BD › Diagnostic Systems › Learning Center › Calendar of Events › National STD Prevention Conference
Learning Center

National STD Prevention Conference
March 10 — 13
   

BD Diagnostics
is pleased to invite you to a
Lunch Symposium
at the
2008 National STD Prevention Conference
Hilton Chicago
Tuesday, March 11, 2008
11:45 am — 1:00 pm

Expanding the Use of Sample Types for Nucleic Acid Amplification Tests
John Papp, PhD, Team Lead, Chlamydia and Gonorrhea Laboratory, DSDTP, CDC

  • Screening for chlamydia; current and desired coverage
  • NAATs allow programs to expand screening since non- or less-invasive specimens can be used
  • NAATs are sophisticated and can only be used in labs that can perform high complexity tests as regulated by CLIA

Costs Associated With Less Sensitive Non-NAAT Tests
Tom Gift, PhD, Health Economist, DSDTP, CDC
  • Cheaper tests are available but may not be cost effective in finding chlamydial infections
  • Cost per treated chlamydia case versus sequelae

The Shift Towards NAATs in California
Dennis V. Ferrero, MPH, Executive Director, California Association of Public Health Laboratory Directors
  • NAATs used in California pre-2002 when CDC recommended NAATs as the test of choice for chlamydia screening
  • Current NAAT usage in California
  • Barriers that labs encountered when switching technology
    • CLIA verification study
    • Change in specimen type
    • Change in lab slips (perhaps an increase in the number of rejected specimens due to improper collection, specimen type or missing lab slip information)
    • Clinician education

Can NAATs Be Used in Indian Country?
Steven Shapiro, Infertility Prevention Program Coordinator, DSDTP, CDC
Scott Tulloch, MPH, Public Health Advisor, DSDTP, CDC
  • Current diagnostic and screening procedures for detecting chlamydia in Indian Country
  • Laboratory capacity (testing in Indian Country or the local PHL)
  • Barriers
    • Cost, technical training, building requirements, etc

Assessment of STD Laboratory Services in the U.S. Jurisdictions of the Pacific Islands
Rick Steece, PhD, D(ABMM), National Chlamydia Laboratory Coordinator, CDC National Infertility Prevention Project
  • Laboratory capacity in the U.S. jurisdictions of the Pacific Islands
    • Current practices
    • CLIA regulated vs non-CLIA regulated
    • Physical structure
    • Training / support
  • Barriers
    • Need for ongoing support / reagent shipments
    • Laboratory structures may not be suitable to NAATs
    • Need for training and QC program